Is VIR or VRAX more undervalued in 2026?

CirclFi compares Vir Biotechnology, Inc. (VIR) and Virax Biolabs Group Limited (VRAX) using 13 institutional-grade valuation models. VIR has a Quality of Company score of 7.0/10 while VRAX scores 1.6/10.

Which is a better buy — VIR or VRAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VIR and VRAX valuations compare?

VIR at $9.55 and VRAX at $0.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VIR vs VRAX Valuation Comparison 2026 — Intrinsic Value Analysis

VIR

Biotechnology

Vir Biotechnology, Inc.

Quality

7.0

out of 10

Value Trap

SAFE

Price

$9.55

Last close

Models

11/13

Active

VRAX

Biotechnology

Virax Biolabs Group Limited

Quality

1.6

out of 10

Value Trap

SAFE

Price

$0.21

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	VIR Fair Value	VIR Upside	VRAX Fair Value	VRAX Upside
Bayesian DCF	Intrinsic	$2.52	-73.6%	$0.06	-73.5%
Earnings Power Value	Intrinsic	$5.74	-42.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$9.81	+2.7%	$0.28	+125.8%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VIR vs VRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VIR vs VRAX — Which Stock Is More Undervalued?

VIR scores higher with a 7.0/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vir Biotechnology, Inc. (VIR) and Virax Biolabs Group Limited (VRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VIR currently trades at $9.55 with a QOC of 7.0/10, while VRAX trades at $0.21 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).